Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 4 From the TACTICS TIMI-18 trial. Kaplan-Meier analysis of the probability of event-free survival for the triple composite end point of death, MI, and biomarker-positive ACS during six months of follow-up, showing a significant benefit for the routine invasive strategy. CI = confidence interval; MI = myocardial infarction; OR = odds ratio; TACTICS TIMI = Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy–Thrombolysis in Myocardial Infarction trial. Adapted with permission from Cannon CP, Weintraub WS, Demopoulos LA, et al., for the TACTICS–Thrombolysis in Myocardial Infarction-18 investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879–87. Copyright © 2002, Massachusetts Medical Society. All rights reserved.
